Reduced baroreflex sensitivity and increased splenic activity in patients with severe obstructive sleep apnea

Yannick Kaiser, Kim E. Dzobo, Madeline J. L. Ravesloot, Nick S. Nurmohamed, Didier Collard, Renate M. Hoogeveen, Hein J. Verberne, Nynke Dijkstra, Nico de Vries, Paul Bresser, Jeffrey Kroon, Erik S. G. Stroes, Herre J. Reesink

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)

Abstract

Background and aims: Severe obstructive sleep apnea (OSA) is associated with an increased risk of cardiovascular disease. Experimental evidence suggests that this risk may be mediated by chronic sympathetic hyperactivation and systemic inflammation, but the precise mechanisms remain to be unraveled. Our aim was to evaluate whether severe OSA patients are characterized by increased sympathetic and hematopoietic activity, potentially driving atherosclerosis. Methods: Untreated patients with severe OSA (apnea-hypopnea index (AHI) > 30 per hour) were matched with mild OSA patients (AHI<15 & >5 per hour) according to age, sex, and body mass index. Study objectives were to assess baroreflex sensitivity (BRS) and heart-rate variability (HRV) using continuous finger blood pressure measurements, hematopoietic activity in the bone marrow and spleen, and arterial inflammation with 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). Results: A total of 34 subjects, 17 per group, were included in the analysis. Mean age was 60.7 ± 6.2 years, 24 (70.6%) were male. Mean AHI was 40.5 ± 12.6 per hour in the severe OSA group, and 10.5 ± 3.4 per hour in the mild OSA group. Participants with severe OSA were characterized by reduced BRS (5.7 [4.6–7.8] ms/mmHg in severe vs 8.2 [6.9–11.8] ms/mmHg in mild OSA, p = 0.033) and increased splenic activity (severe OSA 18F-FDG uptake 3.56 ± 0.77 vs mild OSA 3.01 ± 0.68; p = 0.036). HRV, bone marrow activity and arterial inflammation were comparable between groups. Conclusions: Patients with severe OSA are characterized by decreased BRS and increased splenic activity. Randomized controlled trials are warranted to assess whether OSA treatment reduces sympathetic and splenic activity.
Original languageEnglish
Pages (from-to)7-12
Number of pages6
JournalAtherosclerosis
Volume344
Early online date21 Jan 2022
DOIs
Publication statusPublished - 1 Mar 2022

Keywords

  • Arterial inflammation
  • F-FDG PET/CT
  • Hematopoietic activity
  • Obstructive sleep apnea syndrome
  • Sympathetic activity

Cite this